Literature DB >> 23419049

Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

W Ageno1, M Crowther, T Baglin, A Falanga, H Buller, G Palareti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23419049     DOI： 10.1111/jth.12038

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  5 in total

Review 1.  Current state of anticoagulants to treat deep venous thrombosis.

Authors:  Timothy Vo; Sara Vazquez; Matthew T Rondina
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

2.  Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.

Authors:  Semira Abdi Beshir; Kok-Han Chee; Yoke-Lin Lo
Journal:  Int J Clin Pharm       Date:  2016-07-23

Review 3.  Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.

Authors:  Allison E Burnett; Charles E Mahan; Sara R Vazquez; Lynn B Oertel; David A Garcia; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

Review 4.  Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA).

Authors:  Tomas Salmonson; Jean-Michel Dogné; Heidi Janssen; Juan Garcia Burgos; Paul Blake
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2016-12-25

5.  Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis.

Authors:  Abdulrhman Al Rowily; Zahraa Jalal; Malcolm J Price; Mohammed H Abutaleb; Hind Almodiaemgh; Maha Al Ammari; Vibhu Paudyal
Journal:  Eur J Clin Pharmacol       Date:  2021-12-22       Impact factor: 2.953
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.